Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yanli Wang, Jinling Xue, Zhengjie Su, Yingzi Cui, Guangwen Liu, Wei Yang, Zhengzhi Liu, Jiahui Chen, Qing Ren, Shuang Yu, Yang Cheng, Yannan Zhou, Wanhua Wang, Xuesong Chen, Dongmei Qu, Qiaohuan Deng, Yicheng Zhao & Haimiao Yang. (2023) Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects. Expert Opinion on Investigational Drugs 32:3, pages 263-270.
Read now
Read now
Gabriel Tao, Junqing Huang, Bhagavatula Moorthy, Cathryn Wang, Ming Hu, Song Gao & Romi Ghose. (2020) Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opinion on Drug Metabolism & Toxicology 16:11, pages 1109-1124.
Read now
Read now
Juan Luis Steegmann, Francisco Cervantes, Philipp le Coutre, Kimmo Porkka & Giuseppe Saglio. (2012) Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leukemia & Lymphoma 53:12, pages 2351-2361.
Read now
Read now
Derek R Duckett & Michael D Cameron. (2010) Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1175-1193.
Read now
Read now
Articles from other publishers (21)
Khalid Alhazzani, Salah Q Alrewily, Khaldoon Aljerian, Khaled Alhosaini, Mohammad M. Algahtani, Mohammed Fhad Almutery, Abdullah S Alhamed, Ahmed Nadeem, Moureq R. Alotaibi & Ahmed Z. Alanazi. (2023) Hydroxychloroquine ameliorates dasatinib-induced liver injury via decrease in hepatic lymphocytes infiltration. Human & Experimental Toxicology 42.
Crossref
Crossref
Mudassar Shahid, Ajaz Ahmad, Mohammad Raish, Yousef A Bin Jardan, Khalid M. Alkharfy, Abdul Ahad, Mohd Abul Kalam, Mushtaq Ahmad Ansari, Muzaffer Iqbal, Naushad Ali & Fahad I. Al-Jenoobi. (2023) Herb-drug interaction: Effect of sinapic acid on the pharmacokinetics of dasatinib in rats. Saudi Pharmaceutical Journal 31:11, pages 101819.
Crossref
Crossref
Mohammad Raish, Ajaz Ahmad, Mudassar Shahid, Yousef A. Bin Jardan, Abdul Ahad, Mohd Abul Kalam, Mushtaq Ahmad Ansari, Muzaffar Iqbal, Naushad Ali, Khalid M. Alkharfy & Fahad I. Al-Jenoobi. (2023) Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. Molecules 28:4, pages 1602.
Crossref
Crossref
Fang Cheng, Qiling Xu, Qiang Li, Zheng Cui, Weiming Li & Fang Zeng. (2023) Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. Frontiers in Oncology 13.
Crossref
Crossref
Morgane Clément, Jean-Paul Cervoni, Florian Renosi, Thierry Thévenot, Sophie Felix, Alexandre Doussot, Bruno Heyd, Éric Deconinck & Vincent Di Martino. (2022) Acute fulminant hepatitis related to the use of dasatinib: First case report. Clinics and Research in Hepatology and Gastroenterology 46:8, pages 102004.
Crossref
Crossref
Zahra Nekoukar, Minoo Moghimi & Ebrahim Salehifar. (2021) A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. BLOOD RESEARCH 56:4, pages 229-242.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Zhen Wang, Yuyi Feng, Yaqin Jia, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2021) Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia. JAMA Network Open 4:7, pages e2120165.
Crossref
Crossref
Camille Houron, Marie Danielou, Olivier Mir, Bernard Fromenty, Gabriel Perlemuter & Cosmin Sebastian Voican. (2021) Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Critical Reviews in Oncology/Hematology 157, pages 103127.
Crossref
Crossref
Xujun Liang, Pengfei Zhang, Jun Li, Ying Fu, Lingzhi Qu, Yongheng Chen & Zhuchu Chen. (2019) Learning important features from multi-view data to predict drug side effects. Journal of Cheminformatics 11:1.
Crossref
Crossref
Nelia Hernandez. (2017) Hepatotoxicity of New Antitumor Agents. Current Hepatology Reports 16:4, pages 293-297.
Crossref
Crossref
Chalermrat Bunchorntavakul & K. Rajender Reddy. (2017) Drug Hepatotoxicity. Clinics in Liver Disease 21:1, pages 115-134.
Crossref
Crossref
Fidencio Davalos, Benjamin Chaucer, Wahib Zafar, Shamim Salman & Jay Nfonoyim. (2016) Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug. Translational Oncology 9:3, pages 248-250.
Crossref
Crossref
Xiaochun Yang, Jincheng Wang, Jiabin Dai, Jinjin Shao, Jian Ma, Chao Chen, Shenglin Ma, Qiaojun He, Peihua Luo & Bo Yang. (2015) Autophagy protects against dasatinib-induced hepatotoxicity via p38 signaling. Oncotarget 6:8, pages 6203-6217.
Crossref
Crossref
Colin F SpraggsChun-Fang Xu & Christine M Hunt. (2013) Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics 14:5, pages 541-554.
Crossref
Crossref
Cen Xie, Jialan Zhou, Zitao Guo, Xingxing Diao, Zhiwei Gao, Dafang Zhong, Haoyuan Jiang, Lijia Zhang & Xiaoyan Chen. (2013) Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. British Journal of Pharmacology 168:7, pages 1687-1706.
Crossref
Crossref
Tao Xue, Peihua Luo, Hong Zhu, Yuqin Zhao, Honghai Wu, Renhua Gai, Youping Wu, Bo Yang, Xiaochun Yang & Qiaojun He. (2012) Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes. Toxicology and Applied Pharmacology 261:3, pages 280-291.
Crossref
Crossref
Jenny J. Fischer, Christian Dalhoff, Anna K. Schrey, Olivia Y. Graebner ne? Baessler, Simon Michaelis, Kathrin Andrich, Mirko Glinski, Friedrich Kroll, Michael Sefkow, Mathias Dreger & Hubert Koester. (2011) Dasatinib, imatinib and staurosporine capture compounds ? Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS). Journal of Proteomics 75:1, pages 160-168.
Crossref
Crossref
Kevin J. Wells-Knecht, Gregory R. Ott, Mangeng Cheng, Gregory J. Wells, Henry J. Breslin, Diane E. Gingrich, Linda Weinberg, Eugen F. Mesaros, Zeqi Huang, Mehran Yazdanian, Mark A. Ator, Lisa D. Aimone, Kelli Zeigler & Bruce D. Dorsey. (2011) 2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation. Chemical Research in Toxicology 24:11, pages 1994-2003.
Crossref
Crossref
Xiaohai Li, Yuanjun He, Claudia H. Ruiz, Marcel Koenig & Michael D. Cameron. (2009) Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways. Drug Metabolism and Disposition 37:6, pages 1242-1250.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:2.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Zhen Wang, Yuyi Feng, Yaqin Jia, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2021) Relative Risk of Hepatotoxicity Associated With BCR-ABL Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. SSRN Electronic Journal.
Crossref
Crossref